Topic: management changes
Call it a swap. Alexander Hardy is taking the top spot at Genentech in an executive shuffle triggered by the departure of Dan O'Day.
Vertex exec Ian Smith only just stepped into the company’s interim CFO role alongside his COO title. But now, he’s been fired from both positions.
The four-year GSK chairman joined the company when the drugmaker was reeling from bribery scandals and poor financial performance.
With key commercial cog Mark Mallon bound for Ironwood’s CEO spot, AstraZeneca is reorganizing into two new R&D and commercial lineups.
The first week of 2019 looks a lot like 2018 in at least one regard: A Big Pharma company’s commercial head is on the move.
FiercePharma’s most-read headlines of 2018 include industry themes that dominated the year's news or return time and again—and, of course, scandals.
Merck & Co. boasted some major sales success this year, but the company’s commercial organization will still get a makeover for 2019.
AbbVie CFO Bill Chase will retire in 2019 after helming finance since the company's birth in 2013. He'll be replaced by controller Robert Michael.
Hours after Pfizer unveiled its CEO succession plan, industry watchers had one key question: Will incoming chief Albert Bourla chase M&A?
After steering Pfizer through nine years of selloffs, spinoffs, reorgs, drug launches, patent losses, dealmaking—and one big deal that didn’t—CEO Ian Read is stepping aside.